Silencing of amyloid precursor protein expression using a new engineered delta ribozyme

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Alzheimer's disease (AD) is linked to elevated amyloid-beta (Aβ) peptide levels, which aggregate and cause neurotoxicity.
• Amyloid precursor protein (APP) is the source of Aβ peptides, particularly Aβ(40-42).
• Reducing Aβ accumulation may offer a therapeutic strategy for AD.

Purpose of the Study:

• To investigate a novel approach for lowering Aβ levels in the brain.
• To target the initial step of the Aβ cascade by reducing APP gene expression.

Main Methods:

• Engineered specific SOFA-HDV ribozymes designed to decrease APP mRNA levels.
• Utilized neuronal cells to test the efficacy of the engineered ribozymes.

Main Results:

• The developed APP-ribozymes effectively reduced APP mRNA and protein levels in neuronal cells.
• A significant decrease in amyloid-beta (Aβ) levels was observed following ribozyme treatment.
• SOFA-HDV ribozymes demonstrated effectiveness in lowering key markers associated with Alzheimer's disease.

Conclusions:

• Targeting APP gene expression with SOFA-HDV ribozymes is a viable strategy to reduce Aβ levels.
• This catalytic RNA-based approach holds potential for developing new protective treatments for Alzheimer's disease.
• The findings provide a foundation for future therapeutic interventions aimed at mitigating AD pathology.